O	0	10	Comparison
O	11	13	of
O	14	17	the
O	18	29	Performance
O	30	32	of
O	33	34	6
B-intervention	35	45	Prognostic
I-intervention	46	56	Signatures
O	57	60	for
O	61	69	Estrogen
O	70	78	Receptor
O	78	79	-
O	79	87	Positive
O	88	94	Breast
O	95	101	Cancer
O	101	102	:
O	103	104	A
O	105	114	Secondary
O	115	123	Analysis
O	124	126	of
O	127	128	a
O	129	139	Randomized
O	140	148	Clinical
O	149	154	Trial
O	154	155	.

O	156	164	Multiple
O	165	174	molecular
O	175	185	signatures
O	186	189	are
O	190	199	available
O	200	203	for
O	204	212	managing
O	213	221	estrogen
O	222	230	receptor
O	231	232	(
O	232	234	ER
O	234	235	)
O	235	236	-
O	236	244	positive
O	245	251	breast
O	252	258	cancer
O	259	262	but
O	263	267	with
O	268	274	little
O	275	281	direct
O	282	293	comparative
O	294	305	information
O	306	308	to
O	309	314	guide
O	315	318	the
O	319	326	patient
O	326	327	'
O	327	328	s
O	329	335	choice
O	335	336	.

O	337	339	To
O	340	347	conduct
O	348	349	a
O	350	356	within
O	356	357	-
O	357	364	patient
O	365	375	comparison
O	376	378	of
O	379	382	the
O	383	393	prognostic
O	394	399	value
O	400	402	of
O	403	404	6
O	405	414	multigene
O	415	425	signatures
O	426	428	in
O	429	434	women
O	435	439	with
O	440	445	early
O	446	448	ER
O	448	449	-
O	449	457	positive
O	458	464	breast
O	465	471	cancer
O	472	475	who
O	476	484	received
O	485	494	endocrine
O	495	502	therapy
O	503	506	for
O	507	508	5
O	509	514	years
O	514	515	.

O	516	520	This
O	521	534	retrospective
O	535	544	biomarker
O	545	553	analysis
O	554	562	included
B-total-participants	563	566	774
B-eligibility	567	581	postmenopausal
I-eligibility	582	587	women
I-eligibility	588	592	with
I-eligibility	593	595	ER
I-eligibility	595	596	-
I-eligibility	596	604	positive
I-eligibility	605	610	ERBB2
I-eligibility	611	612	(
I-eligibility	612	620	formerly
I-eligibility	621	625	HER2
I-eligibility	625	626	)
I-eligibility	626	627	-
I-eligibility	627	635	negative
I-eligibility	636	642	breast
I-eligibility	643	649	cancer
O	649	650	.

O	651	655	This
O	656	664	analysis
O	665	668	was
O	669	678	performed
O	679	681	as
O	682	683	a
O	684	694	preplanned
O	695	704	secondary
O	705	710	study
O	711	713	of
O	714	718	data
O	719	723	from
O	724	727	the
O	728	739	Anastrozole
O	740	742	or
O	743	752	Tamoxifen
O	753	758	Alone
O	759	761	or
O	762	770	Combined
O	771	781	randomized
O	782	790	clinical
O	791	796	trial
O	797	806	comparing
O	807	808	5
O	808	809	-
O	809	813	year
O	814	823	treatment
O	824	828	with
O	829	840	anastrozole
O	841	843	vs
O	844	853	tamoxifen
O	854	858	with
O	859	861	10
O	861	862	-
O	862	866	year
O	867	873	follow
O	873	874	-
O	874	876	up
O	877	881	data
O	881	882	.

O	883	886	The
O	887	897	signatures
O	898	906	included
O	907	910	the
O	911	919	Oncotype
O	920	922	Dx
O	923	933	recurrence
O	934	939	score
O	939	940	,
O	941	946	PAM50
O	946	947	-
O	947	952	based
O	953	961	Prosigna
O	962	966	risk
O	967	969	of
O	970	980	recurrence
O	981	982	(
O	982	985	ROR
O	985	986	)
O	986	987	,
O	988	994	Breast
O	995	1001	Cancer
O	1002	1007	Index
O	1008	1009	(
O	1009	1012	BCI
O	1012	1013	)
O	1013	1014	,
O	1015	1026	EndoPredict
O	1027	1028	(
O	1028	1034	EPclin
O	1034	1035	)
O	1035	1036	,
O	1037	1045	Clinical
O	1046	1055	Treatment
O	1056	1061	Score
O	1061	1062	,
O	1063	1066	and
O	1067	1068	4
O	1068	1069	-
O	1069	1075	marker
O	1076	1095	immunohistochemical
O	1096	1101	score
O	1101	1102	.

O	1103	1107	Data
O	1108	1112	were
O	1113	1122	collected
O	1123	1127	from
O	1128	1135	January
O	1136	1140	2009
O	1140	1141	,
O	1142	1149	through
O	1150	1155	April
O	1156	1160	2015
O	1160	1161	.

O	1162	1165	The
O	1166	1173	primary
O	1174	1183	objective
O	1184	1187	was
O	1188	1190	to
O	1191	1198	compare
O	1199	1202	the
O	1203	1213	prognostic
O	1214	1219	value
O	1220	1222	of
O	1223	1228	these
O	1229	1239	signatures
O	1240	1242	in
O	1243	1251	addition
O	1252	1254	to
O	1255	1258	the
O	1259	1267	Clinical
O	1268	1277	Treatment
O	1278	1283	Score
O	1284	1285	(
O	1285	1290	nodal
O	1291	1297	status
O	1297	1298	,
O	1299	1304	tumor
O	1305	1309	size
O	1309	1310	,
O	1311	1316	grade
O	1316	1317	,
O	1318	1321	age
O	1321	1322	,
O	1323	1326	and
O	1327	1336	endocrine
O	1337	1346	treatment
O	1346	1347	)
O	1348	1351	for
O	1352	1359	distant
O	1360	1370	recurrence
O	1371	1374	for
O	1375	1376	0
O	1377	1379	to
O	1380	1382	10
O	1383	1388	years
O	1389	1392	and
O	1393	1394	5
O	1395	1397	to
O	1398	1400	10
O	1401	1406	years
O	1407	1412	after
O	1413	1422	diagnosis
O	1422	1423	.

O	1424	1434	Likelihood
O	1435	1440	ratio
O	1441	1442	(
O	1442	1444	LR
O	1444	1445	)
O	1446	1456	statistics
O	1457	1461	were
O	1462	1466	used
O	1467	1471	with
O	1472	1475	the
O	1476	1477	χ
O	1477	1478	2
O	1479	1483	test
O	1484	1487	and
O	1488	1489	C
O	1490	1497	indexes
O	1498	1500	to
O	1501	1507	assess
O	1508	1511	the
O	1512	1522	prognostic
O	1523	1528	value
O	1529	1531	of
O	1532	1536	each
O	1537	1546	signature
O	1546	1547	.

O	1548	1550	In
O	1551	1555	this
O	1556	1561	study
O	1562	1564	of
B-total-participants	1565	1568	774
O	1569	1583	postmenopausal
O	1584	1589	women
O	1590	1594	with
O	1595	1597	ER
O	1597	1598	-
O	1598	1606	positive
O	1606	1607	,
O	1608	1613	ERBB2
O	1613	1614	-
O	1614	1622	negative
O	1623	1630	disease
O	1631	1632	(
O	1632	1636	mean
O	1637	1638	[
O	1638	1640	SD
O	1640	1641	]
O	1642	1645	age
O	1645	1646	,
B-age	1647	1649	64
I-age	1649	1650	.
I-age	1650	1651	1
I-age	1652	1653	[
I-age	1653	1654	8
I-age	1654	1655	.
I-age	1655	1656	1
I-age	1656	1657	]
I-age	1658	1663	years
O	1663	1664	)
O	1664	1665	,
O	1666	1669	591
O	1670	1671	(
O	1671	1675	mean
O	1676	1677	[
O	1677	1679	SD
O	1679	1680	]
O	1681	1684	age
O	1684	1685	,
B-age	1686	1688	63
I-age	1688	1689	.
I-age	1689	1690	4
I-age	1691	1692	[
I-age	1692	1693	7
I-age	1693	1694	.
I-age	1694	1695	9
I-age	1695	1696	]
I-age	1697	1702	years
O	1702	1703	)
O	1704	1707	had
O	1708	1712	node
O	1712	1713	-
O	1713	1721	negative
O	1722	1729	disease
O	1729	1730	.

O	1731	1734	The
O	1735	1745	signatures
O	1746	1755	providing
O	1756	1759	the
O	1760	1764	most
O	1765	1775	prognostic
O	1776	1787	information
O	1788	1792	were
O	1793	1796	the
B-outcome-Measure	1797	1800	ROR
O	1801	1802	(
O	1802	1808	hazard
O	1809	1814	ratio
O	1815	1816	[
O	1816	1818	HR
O	1818	1819	]
O	1819	1820	,
O	1821	1822	2
O	1822	1823	.
O	1823	1825	56
O	1825	1826	;
O	1827	1829	95
O	1829	1830	%
O	1831	1833	CI
O	1833	1834	,
O	1835	1836	1
O	1836	1837	.
O	1837	1839	96
O	1839	1840	-
O	1840	1841	3
O	1841	1842	.
O	1842	1844	35
O	1844	1845	)
O	1845	1846	,
O	1847	1855	followed
O	1856	1858	by
O	1859	1862	the
B-outcome	1863	1866	BCI
O	1867	1868	(
O	1868	1870	HR
O	1870	1871	,
O	1872	1873	2
O	1873	1874	.
O	1874	1876	46
O	1876	1877	;
O	1878	1880	95
O	1880	1881	%
O	1882	1884	CI
O	1884	1885	,
O	1886	1887	1
O	1887	1888	.
O	1888	1890	88
O	1890	1891	-
O	1891	1892	3
O	1892	1893	.
O	1893	1895	23
O	1895	1896	)
O	1897	1900	and
B-outcome	1901	1907	EPclin
O	1908	1909	(
O	1909	1911	HR
O	1911	1912	,
O	1913	1914	2
O	1914	1915	.
O	1915	1917	14
O	1917	1918	;
O	1919	1921	95
O	1921	1922	%
O	1923	1925	CI
O	1925	1926	,
O	1927	1928	1
O	1928	1929	.
O	1929	1931	71
O	1931	1932	-
O	1932	1933	2
O	1933	1934	.
O	1934	1936	68
O	1936	1937	)
O	1937	1938	.

O	1939	1943	Each
O	1944	1952	provided
O	1953	1966	significantly
B-outcome	1967	1971	more
I-outcome	1972	1983	information
I-outcome	1984	1988	than
I-outcome	1989	1992	the
I-outcome	1993	2001	Clinical
I-outcome	2002	2011	Treatment
I-outcome	2012	2017	Score
O	2018	2019	(
O	2019	2021	HR
O	2021	2022	,
O	2023	2024	1
O	2024	2025	.
O	2025	2027	99
O	2027	2028	;
O	2029	2031	95
O	2031	2032	%
O	2033	2035	CI
O	2035	2036	,
O	2037	2038	1
O	2038	2039	.
O	2039	2041	58
O	2041	2042	-
O	2042	2043	2
O	2043	2044	.
O	2044	2046	50
O	2046	2047	)
O	2047	2048	,
O	2049	2052	the
B-outcome	2053	2063	recurrence
I-outcome	2064	2069	score
O	2070	2071	(
O	2071	2073	HR
O	2073	2074	,
O	2075	2076	1
O	2076	2077	.
O	2077	2079	69
O	2079	2080	;
O	2081	2083	95
O	2083	2084	%
O	2085	2087	CI
O	2087	2088	,
O	2089	2090	1
O	2090	2091	.
O	2091	2093	40
O	2093	2094	-
O	2094	2095	2
O	2095	2096	.
O	2096	2098	03
O	2098	2099	)
O	2099	2100	,
O	2101	2104	and
O	2105	2108	the
B-outcome	2109	2110	4
I-outcome	2110	2111	-
I-outcome	2111	2117	marker
I-outcome	2118	2137	immunohistochemical
I-outcome	2138	2143	score
O	2144	2145	(
O	2145	2147	HR
O	2147	2148	,
O	2149	2150	1
O	2150	2151	.
O	2151	2153	95
O	2153	2154	;
O	2155	2157	95
O	2157	2158	%
O	2159	2161	CI
O	2161	2162	,
O	2163	2164	1
O	2164	2165	.
O	2165	2167	55
O	2167	2168	-
O	2168	2169	2
O	2169	2170	.
O	2170	2172	45
O	2172	2173	)
O	2173	2174	.

O	2175	2188	Substantially
O	2189	2193	less
O	2194	2205	information
O	2206	2209	was
O	2210	2218	provided
O	2219	2221	by
O	2222	2225	all
O	2226	2227	6
O	2228	2237	molecular
O	2238	2243	tests
O	2244	2247	for
O	2248	2251	the
O	2252	2255	183
O	2256	2264	patients
O	2265	2269	with
O	2270	2271	1
O	2272	2274	to
O	2275	2276	3
O	2277	2285	positive
O	2286	2291	nodes
O	2291	2292	,
O	2293	2296	but
O	2297	2300	the
O	2301	2304	BCI
O	2305	2306	(
O	2306	2307	Δ
O	2307	2309	LR
O	2310	2311	χ
O	2311	2312	2
O	2313	2314	=
O	2315	2316	9
O	2316	2317	.
O	2317	2318	2
O	2318	2319	)
O	2320	2323	and
O	2324	2330	EPclin
O	2331	2332	(
O	2332	2333	Δ
O	2333	2335	LR
O	2336	2337	χ
O	2337	2338	2
O	2339	2340	=
O	2341	2342	7
O	2342	2343	.
O	2343	2344	4
O	2344	2345	)
O	2346	2354	provided
O	2355	2359	more
O	2360	2370	additional
O	2371	2381	prognostic
O	2382	2393	information
O	2394	2398	than
O	2399	2402	the
O	2403	2408	other
O	2409	2419	signatures
O	2419	2420	.

O	2421	2424	For
O	2425	2430	women
O	2431	2435	with
O	2436	2440	node
O	2440	2441	-
O	2441	2449	negative
O	2450	2457	disease
O	2457	2458	,
O	2459	2462	the
O	2463	2466	ROR
O	2466	2467	,
O	2468	2471	BCI
O	2471	2472	,
O	2473	2476	and
O	2477	2483	EPclin
O	2484	2488	were
O	2489	2502	significantly
O	2503	2507	more
O	2508	2518	prognostic
O	2519	2522	for
O	2523	2530	overall
O	2531	2534	and
O	2535	2539	late
O	2540	2547	distant
O	2548	2558	recurrence
O	2558	2559	.

O	2560	2563	For
O	2564	2569	women
O	2570	2574	with
O	2575	2576	1
O	2577	2579	to
O	2580	2581	3
O	2582	2590	positive
O	2591	2596	nodes
O	2596	2597	,
O	2598	2605	limited
O	2606	2617	independent
O	2618	2629	information
O	2630	2633	was
O	2634	2643	available
O	2644	2648	from
O	2649	2652	any
O	2653	2657	test
O	2657	2658	.

O	2659	2664	These
O	2665	2669	data
O	2670	2675	might
O	2676	2680	help
O	2681	2692	oncologists
O	2693	2696	and
O	2697	2705	patients
O	2706	2708	to
O	2709	2715	choose
O	2716	2719	the
O	2720	2724	most
O	2725	2736	appropriate
O	2737	2741	test
O	2742	2746	when
O	2747	2758	considering
O	2759	2771	chemotherapy
O	2772	2775	use
O	2776	2779	and
O	2779	2780	/
O	2780	2782	or
O	2783	2791	extended
O	2792	2801	endocrine
O	2802	2809	therapy
O	2809	2810	.
O	2811	2817	isrctn
O	2817	2818	.
O	2818	2821	com
O	2822	2832	Identifier
O	2832	2833	:
O	2834	2848	ISRCTN18233230
O	2848	2849	.
